Figure 1.
Distribution of patients with AML included in the study within the ELN 2017 risk categories. *Patients allocated to this category have been identified by NPM1 and FLT3-ITD mutational status. **Patients with ASXL1 mutation without RUNX1 mutation. ***Patients with TP53 mutation or abn(17p) without complex karyotype.

Distribution of patients with AML included in the study within the ELN 2017 risk categories. *Patients allocated to this category have been identified by NPM1 and FLT3-ITD mutational status. **Patients with ASXL1 mutation without RUNX1 mutation. ***Patients with TP53 mutation or abn(17p) without complex karyotype.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal